Evidence map›Paper›PMID 38426437›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2024

Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.

Christopher E McMurran, Trisha Mukherjee, J William L Brown, Alasdair J Coles, Nick G Cunniffe

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christopher E McMurranDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0002-8710-0930
Trisha MukherjeeDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
J William L BrownDepartment of Clinical Neurosciences, University of Cambridge, Cambridge. UK/NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London (UCL) Institute of Neurology, London. UK/Clinical Outcomes Research (CORe) Unit, The University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-7737-5834
Alasdair J ColesDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Nick G CunniffeDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0002-7562-2838
University of Cambridge · GBThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Cambridge Centre for Myelin Repair One (CCMR-One) trial showed that 6 months of bexarotene reduces visual evoked potential (VEP) latency in people with relapsing-remitting multiple sclerosis (MS). In a single-centre follow-up study of these participants, we re-examined full-field VEP and clinical assessments. Twenty participants (12 bexarotene and 8 placebo) were seen on average 27 months after their trial involvement. In an analysis of all eyes with recordable signal (24 bexarotene and 14 placebo), the adjusted bexarotene-placebo treatment difference in P100 latency was -7.79 (95% confidence interval (CI) = -14.76, -0.82) ms,

Indexed as

BexaroteneEvoked Potentials, VisualMyelin SheathAdultDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingTetrahydronaphthalenesTreatment OutcomeBexaroteneTetrahydronaphthalenesbexaroteneclinical trialevoked potentialsMultiple sclerosisoptic neuritisremyelinationvisual

Identifiers

PMID38426437
PMCPMC11290016
OpenAlexW4392356327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.